Neurological Disorder Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK.
J Neurochem. 2019 Sep;150(5):612-625. doi: 10.1111/jnc.14713. Epub 2019 Jun 25.
Synucleinopathies including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are characterized by the abnormal accumulation and propagation of α-synuclein (α-syn) pathology in the central and peripheral nervous system as Lewy bodies or glial cytoplasmic inclusions. Several antibodies against α-syn have been developed since it was first detected as the major component of Lewy bodies and glial cytoplasmic inclusions. Over the years, researchers have generated specific antibodies that alleviate the accumulation of intracellular aggregated α-syn and associated pathology in cellular and preclinical models of synucleinopathies. So far, antibodies have been the first choice as tools for research and diagnosis and currently, a wide variety of antibody fragments have been developed as an alternative to full-length antibodies for increasing its therapeutic usefulness. Recently, conformation specific antibody-based approaches have been found to be promising as therapeutic strategies, both to block α-syn aggregation and ameliorate the resultant cytotoxicity, and as diagnostic tools. In this review, we summarize different α-syn specific antibodies and provide their usefulness in tackling synucleinopathies. This article is part of the Special Issue "Synuclein".
包含帕金森病、路易体痴呆和多系统萎缩在内的突触核蛋白病的特征是中枢和外周神经系统中α-突触核蛋白（α-syn）病理学的异常积累和传播，表现为路易体或神经胶质细胞胞质内包涵体。自从首次发现α-syn 是路易体和神经胶质细胞胞质内包涵体的主要成分以来，已经开发了几种针对 α-syn 的抗体。多年来，研究人员已经产生了特异性抗体，可减轻细胞内聚集的α-syn 的积累以及突触核蛋白病的细胞和临床前模型中的相关病理学。到目前为止，抗体一直是作为研究和诊断工具的首选，目前，已经开发出多种抗体片段作为全长抗体的替代品，以增加其治疗用途。最近，基于构象特异性抗体的方法已被发现是有希望的治疗策略，既可以阻止α-syn 聚集，又可以减轻由此产生的细胞毒性，也可以作为诊断工具。在这篇综述中，我们总结了不同的α-syn 特异性抗体，并提供了它们在治疗突触核蛋白病方面的用途。本文是“突触核蛋白”特刊的一部分。
